BiomX Inc. Accelerates Defense Technology Expansion with DFSL Acquisition

Key Points

• BiomX Inc. (NYSE: PHGE) has exercised its exclusive option and entered a definitive agreement to acquire a controlling interest in DFSL, an Israeli defense engineering company.
• The acquisition expands BiomX’s portfolio in the defense sector, specifically focusing on AI-enabled security systems and LADAR (Laser Radar) detection technology.
• DFSL’s LADAR systems provide real-time tracking of aerial and ground threats, complementing BiomX’s recently acquired Zorronet AI command-and-control platform.
• Technologies are designed to function as an integrated system, connecting detection, analysis, and response across defense, critical infrastructure, and first-response applications.
• The deal includes a mix of cash payment, unsecured convertible note, warrants exercisable at \$12 per share, and a bonus payment tied to defined revenue milestones.
• The transaction is subject to regulatory approval in Israel and shareholder approval as required by NYSE American.

Detailed Analysis for Investors

BiomX Inc. has taken a significant step towards establishing itself as a key player in the defense technology market. By acquiring a controlling stake in DFSL, the company is reinforcing its position with advanced, AI-powered security systems that integrate detection, analysis, and response capabilities.

DFSL’s LADAR Technology: DFSL specializes in high-precision LADAR (Laser Radar) detection systems, which are deployed in perimeter security, critical infrastructure, and counter-UAS (Unmanned Aerial Systems) markets. This technology enables real-time identification and tracking of threats—both aerial and ground—by combining laser-based sensing with proprietary AI algorithms that process information within the sensor itself. This approach significantly reduces false positives, a common challenge in modern security systems, and improves operational effectiveness. DFSL’s LADAR platform boasts demonstrated accuracy of approximately 99% in real-world applications.

Complementary Integration with Zorronet: BiomX recently acquired Zorronet, an AI-driven command-and-control platform capable of integrating data from cameras, drones, sensors, and other systems into a unified operational intelligence environment. By combining DFSL’s LADAR detection systems with Zorronet’s platform, BiomX aims to create a comprehensive solution for real-time detection, validation, and response. This unified functional chain—from detection to inference and action—will enable security and defense operators to act with greater speed, accuracy, and confidence across various scenarios, including protection of facilities, critical infrastructure, and national borders.

DFSL’s Track Record: Founded in 1995, DFSL has deployed its technology across Israel, Africa, and major transportation systems such as the Los Angeles Metro. The company’s technology is protected by a portfolio of patents covering both hardware design and signal processing methodologies, indicating strong intellectual property safeguards.

Deal Structure and Shareholder Impact: The transaction includes a cash payment, an unsecured convertible note, and warrants exercisable at \$12 per share. Importantly, there is a bonus payment tied to defined revenue thresholds, aligning shareholder value with future growth and performance milestones. These elements are designed to incentivize future growth and could be highly relevant for current and prospective shareholders.

Regulatory and Shareholder Approvals: The acquisition is contingent upon regulatory approval in Israel and shareholder approval as required by NYSE American. Any delays or issues in obtaining these approvals could impact the timing and completion of the transaction.

Potential Market Impact: The expansion into defense and AI-enabled security systems positions BiomX to capitalize on growing global demand for real-time detection and validation technologies. The company’s leadership, led by CEO Michael Oster, emphasizes its foundation in real defense experience and the potential for a diversified portfolio in defense, rescue, and security capabilities.

Price-Sensitive Considerations

• The deal structure, including warrants and revenue-tied bonus payments, directly links shareholder value to future performance.
• Demonstrated accuracy of DFSL’s LADAR systems (approx. 99%) and proven deployments in critical infrastructure may enhance BiomX’s competitive advantage and market appeal.
• Integration with Zorronet’s AI platform offers a differentiated, comprehensive solution that could attract new customers and contracts in defense and security sectors.
• Regulatory and shareholder approvals represent potential risks or delays for the transaction’s completion.

Management Commentary

“This transaction reflects how we are building the Company today, with leadership and engineering capabilities grounded in real defense experience. DFSL brings proven technology, real-world deployments, and deep domain expertise, creating a strong foundation for building a diversified portfolio of defense, rescue and security capabilities. In line with growing global demand, we accelerated the exercise of the option in response to evolving defense and security requirements, where the need for real-time detection and validation continues to increase. We see significant potential to expand DFSL’s offerings and integrate its technology into the company’s portfolio.”
— Michael Oster, CEO of BiomX

“Zorronet’s AI-driven platform delivers real-time detection, verification, and decision support. Combined with DFSL’s LADAR detection systems, we will be able to create a more comprehensive and precise rational response. Together, we believe we will enable security and defense operators to act with greater speed, accuracy, and confidence across everything from single facilities to critical infrastructure and national borders.”
— Idan Wasserman, CEO of Zorronet

Investor Contact

For further information, investors can contact:
Yair Ohayon
Investor Relations
[email protected]

Disclaimer

This article contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties, including regulatory and shareholder approvals, integration risks, market and industry conditions, and other factors that may cause actual results to differ materially. Investors are urged to conduct their own due diligence and consult with financial advisors before making investment decisions. BiomX Inc. undertakes no obligation to update any forward-looking statements except as required by law.

View BiomX Inc. Historical chart here